162 related articles for article (PubMed ID: 1834116)
1. Phase II study of fotemustine in recurrent supratentorial malignant gliomas.
Frenay M; Giroux B; Khoury S; Derlon JM; Namer M
Eur J Cancer; 1991; 27(7):852-6. PubMed ID: 1834116
[TBL] [Abstract][Full Text] [Related]
2. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
Beauchesne PD; Taillandier L; Bernier V; Carnin C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
[TBL] [Abstract][Full Text] [Related]
3. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
Fabi A; Metro G; Russillo M; Vidiri A; Carapella CM; Maschio M; Cognetti F; Jandolo B; Mirri MA; Sperduti I; Telera S; Carosi M; Pace A
BMC Cancer; 2009 Mar; 9():101. PubMed ID: 19335893
[TBL] [Abstract][Full Text] [Related]
4. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
[TBL] [Abstract][Full Text] [Related]
5. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
[TBL] [Abstract][Full Text] [Related]
6. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A
J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471
[TBL] [Abstract][Full Text] [Related]
7. Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience.
Gaviani P; Simonetti G; Salmaggi A; Lamperti E; Silvani A
J Neurooncol; 2013 Jul; 113(3):527-9. PubMed ID: 23703296
[No Abstract] [Full Text] [Related]
8. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
9. Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.
Boiardi A; Silvani A; Ciusani E; Watson A; Margison G; Berger E; Lucas C; Giroux B
J Neurooncol; 2001 Apr; 52(2):149-56. PubMed ID: 11508814
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.
Fulton D; Urtasun R; Forsyth P
J Neurooncol; 1996 Feb; 27(2):149-55. PubMed ID: 8699237
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
[TBL] [Abstract][Full Text] [Related]
12. [Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas].
Malhaire JP; Lucas B; Simon H; Person H; Dam-Hieu P; Labat JP
Bull Cancer; 1999 Mar; 86(3):289-94. PubMed ID: 10210763
[TBL] [Abstract][Full Text] [Related]
13. Lecture: fotemustine in brain tumors.
Silvani A; Gaviani P; Lamperti E; Botturi A; Ferrari D; Simonetti G; Salmaggi A
Neurol Sci; 2011 Nov; 32 Suppl 2():S255-7. PubMed ID: 21987288
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of fotemustine in patients with metastatic malignant melanoma.
Falkson CI; Falkson G; Falkson HC
Invest New Drugs; 1994; 12(3):251-4. PubMed ID: 7896545
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer.
Le Cesne A; Chabot G; Bérille J; Lucas C; Baud M; Gouyette A; Marty M; Le Chevalier T
Lung Cancer; 1995 Aug; 13(1):69-78. PubMed ID: 8528641
[TBL] [Abstract][Full Text] [Related]
16. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study.
Sanson M; Ameri A; Monjour A; Sahmoud T; Ronchin P; Poisson M; Delattre JY
Eur J Cancer; 1996 Dec; 32A(13):2229-35. PubMed ID: 9038603
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma.
Lasset C; Merrouche Y; Negrier S; Rebattu P; Berille J; Bizzari JP; Chauvin F; Philip T
Cancer Chemother Pharmacol; 1993; 32(4):329-31. PubMed ID: 8324878
[TBL] [Abstract][Full Text] [Related]
18. High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Marinelli A; Lamberti G; Cerbone L; Cordua N; Buonerba C; Peluso G; Di Lorenzo G; De Placido S
Medicine (Baltimore); 2018 Jul; 97(27):e11254. PubMed ID: 29979390
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.
Pujol JL; Monnier A; Berille J; Cerrina ML; Douillard JY; Rivière A; Grandgirard A; Gouva S; Bizzari JP; Le Chevalier T
Br J Cancer; 1994 Jun; 69(6):1136-40. PubMed ID: 8198982
[TBL] [Abstract][Full Text] [Related]
20. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
